Aly Featured on Hatch-Waxman Influence on BPCIA Litigation

Imron said, “I would say that the BPCIA litigation is Hatch-Waxman on steroids… we’re seeing a lot of brand-versus-brand interactions. They all want to get into the biosimilars game, when not so long ago, they were all making brand drugs, trying to stave off competition.”

“Now, on a brand-versus-brand larger scale, we can leave no stone unturned and be able to investigate a lot of issues and really dig down into the deep issues of invalidity, prior sale, prior use, anything that goes to invalidating those prior patents in the biosimilars world. Those are things that are from the Hatch-Waxman space, but carried over really to a further extent on the biosimilars side.”

Watch the full clip here.